Are there genetic indicators that can help rheumatologists identify the people who are at risk for developing the disease? Are there environmental factors that trigger rheumatoid arthritis (RA)? Simply put, what causes RA and how do we treat and cure it?
Glucocorticoid-Induced Osteoporosis
Osteoporosis is a condition of weak bone caused by a loss of bone mass and a change in bone structure. Glucocorticoid-induced osteoporosis is a form of osteoporosis caused by taking glucocorticoid medications, such as prednisone (Deltasone, Orasone, etc.), prednisolone (Prelone), dexamethasone (Decadron, Hexadrol), and cortisone (Cortone Acetate). These medications are used to help control many rheumatic diseases, including RA, systemic lupus erythematosus, and polymyalgia rheumatica.
Sneak Peak at the 2008 Annual Scientific Meeting
The 2007 ACR/ARHP Annual Scientific Meeting was well received by attendees, and the ACR and the ARHP are building on that foundation by offering a variety of in-depth sessions at the 2008 meeting in San Francisco on October 24–29.
Physician Quality Reporting Initiative (PQRI) Changes for 2008
CMS has announced alternative reporting periods and reporting criteria for the 2008 Physician Quality Reporting Initiative (PQRI).
Tips to Access Journals Online
Online access to Arthritis & Rheumatism and Arthritis Care & Research is a member benefit of the ACR and the ARHP. In order to use this benefit, you must activate your online access by creating a login specifically for the journals through a one-time registration process. Here is a Q&A to help you access journals online.
New Advance Beneficiary Notice
CMS has replaced the general and lab advanced beneficiary notice with the Advance Beneficiary Notice (ABN) of Non-coverage. The new titled notice requires physicians and other healthcare providers to use a new form when services are not expected to be covered by Medicare.
Drug Safety Alerts: Moving Past the Pony Express to the 21st Century safety alerts.
Have you ever wondered why you are able to get up-to-the-minute sports scores, but it could take weeks to receive potentially lifesaving drug safety alerts? (And that is only if your front-office staff is able to separate the “Dear Doctor” letter from junk mail.)
Boost Revenue with Denials Management, Appeals
Denials management and appeals are the two most underestimated processes in rheumatology offices. Most practices lose thousands of dollars every year because they are not following up or writing off denied claims correctly.
Nonsurgical Management of Lumbar Spinal Stenosis
Maura D. Iversen, PT, DPT, SD, MPH, of MGH Institute of Health Professions in Boston, will discuss the nonsurgical management of lumbar spinal stenosis (LSS), epidemiology, and common symptoms associated with this condition during the ARHP rheumatology audioconference on Wednesday, May 21, from noon to 1:00 p.m. (EST). Iversen will provide a summary of nonpharmacologic and nonsurgical interventions to manage LSS—including a summary and evaluation of manual therapy techniques and exercise.
FDA Enforcement Against Injectable Colchicine
The U.S. Food and Drug Administration (FDA) has ordered companies to stop marketing unapproved drug products that contain colchicines in an injectable dosage form.
- « Previous Page
- 1
- …
- 115
- 116
- 117
- 118
- 119
- …
- 133
- Next Page »